Table 1.
The association between the TM6SF2 (Glu167Lys) variant, liver enzymes and plasma lipid levels in the DHS (n=4,587), the Dallas BioBank (n=8,585), and the Copenhagen Study (n=73,532).
| Trait | EE | EK | KK | P-value |
|---|---|---|---|---|
| DHS | ||||
| n | 4,151 | 423 | 13 | - |
| ALT (U) | 23.5 ± 19.9 | 25.8 ± 18.0 | 29.6 ± 26.8 | 0.014 |
| AST (U) | 24.3 ± 20.6 | 25.1 ± 19.6 | 25.6 ± 16.5 | 0.17 |
| ALP (U) | 71.6 ± 26.4 | 68.0 ± 20.9 | 63.6 ± 16.4 | 0.031 |
| LDL-C (mg/dL) | 109 ± 36 | 105 ± 34 | 94 ± 39 | 0.005 |
| Triglyceride (mg/dL) | 123 ± 102 | 118 ± 91 | 130 ± 66 | 0.037 |
| Dallas Biobank (European-Americans) | ||||
| n | 7,416 | 1,112 | 57 | - |
| ALT (U) | 35.9 ± 16.3 | 36.5 ± 15 | 44.8 ± 23.8 | 0.003 |
| AST (U) | 27 ± 13.8 | 26.9 ± 10.7 | 30.2 ± 13.5 | 0.22 |
| ALP (U) | 69 ± 18.9 | 66.9 ± 17.3 | 65.9 ± 19.1 | 1.2 × 10−4 |
| LDL-C (mg/dL) | 107 ± 34 | 105 ± 32 | 97 ± 32 | 0.029 |
| Triglyceride (mg/dL) | 112 ± 79 | 105.3 ± 67 | 97.5 ± 54 | 6.7 × 10−5 |
| Copenhagen Study | ||||
| n | 61,279 | 11,700 | 553 | - |
| ALT (U) | 22.7 ± 17.2 | 23.8 ± 16.0 | 26.7 ± 20.9 | 7.6 × 10−14 |
| AST (U) (n=8,487) | 22.8 ± 13.2 | 23.9 ± 18.6 | 30.0 ± 36.6 | 1.8 × 10−4 |
| ALP (U) | 91.1 ± 37.5 | 89.7 ± 39.1 | 85.0 ± 34.2 | 4.3 × 10−7 |
| LDL-C (mg/dL) | 128 ± 39 | 127 ± 38 | 112 ± 36 | 4.7 × 10−14 |
| Triglyceride (mg/dL) | 152 ± 106 | 148 ± 96 | 133 ± 90 | 3.7 × 10−9 |
Values are means ± s.d. The association was tested using linear regression with adjustment for age, gender, BMI, and ethnicity (where appropriate). A logarithm transformation was applied to traits with non-normal distributions. AST was only measured in a subset of the Copenhagen Study (n=8,487). Ethnic breakdown for the Dallas Heart Study is provided in Supplementary Table 3. ALT, alanine aminotransferase; AST, aspartate transaminase; ALP, alkaline phosphatase; LDL-C, low density lipoprotein-cholesterol.